Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.
Lisocabtagene maraleucel induced high response rates in patients with aggressive relapsed/refractory large B-cell lymphoma.
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.
The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.
Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.
Tanya Siddiqi, MD, discussed the CAR T-cell trial ahead of the ASH Annual Meeting & Exposition in an interview with CancerNetwork®.
Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.
Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.